Aptevo Therapeutics Inc (NASDAQ:APVO) Director Fuad El-Hibri purchased 18,919 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were acquired at an average price of $0.85 per share, for a total transaction of $16,081.15. Following the purchase, the director now directly owns 843,455 shares in the company, valued at $716,936.75. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
APVO opened at $0.86 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.91 and a current ratio of 3.15. Aptevo Therapeutics Inc has a fifty-two week low of $0.67 and a fifty-two week high of $5.80. The company’s fifty day moving average price is $0.83.
Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. The company had revenue of $7.02 million for the quarter, compared to analysts’ expectations of $6.30 million. As a group, equities analysts expect that Aptevo Therapeutics Inc will post -1.4 earnings per share for the current year.
Several research analysts have recently weighed in on the stock. Roth Capital reiterated a “buy” rating on shares of Resverlogix in a research note on Thursday, May 23rd. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Piper Jaffray Companies lifted their target price on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $7.88.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.